Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses Jun 12, 2025 06:01PM
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance May 1, 2025 07:00AM
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 Apr 25, 2025 08:00AM
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference Mar 31, 2025 08:00AM
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress Feb 28, 2025 08:00AM
View Older Stories

Feb 13, 2025 07:00AM Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
Feb 5, 2025 08:00AM Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
Jan 12, 2025 04:00PM Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
Dec 18, 2024 08:00AM Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 7, 2024 12:30PM Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
Oct 30, 2024 07:00AM Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Oct 16, 2024 08:00AM Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
Sep 10, 2024 08:00AM Blueprint Medicines to Present at Upcoming Investor Conferences
Aug 1, 2024 07:00AM Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Jul 18, 2024 08:00AM Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
May 30, 2024 06:01PM Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
May 23, 2024 05:05PM Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Ann
May 23, 2024 10:51AM BPMC INVESTOR ALERT: Andrews & Springer LLC Investigates Blueprint Medicines Corporation
May 20, 2024 08:01AM BPMC Alert: The Law Firm of Andrews & Springer LLC Is Investigating Blueprint Medicines Corporation For Potential Securities Violations and Breaches of Fiduciary Duty
May 6, 2024 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2024 07:00AM Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Apr 18, 2024 08:00AM Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Apr 11, 2024 08:00AM Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Apr 4, 2024 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 6, 2024 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 23, 2024 08:01AM Blueprint Medicines (BPMC) Highlights AYVAKIT Long-Term Efficacy and Safety Data
Feb 23, 2024 08:00AM Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
Feb 15, 2024 07:00AM Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
Feb 5, 2024 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2024 08:00AM Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
Jan 8, 2024 08:07AM Blueprint Medicines (BPMC) Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
Jan 8, 2024 08:00AM Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
Jan 5, 2024 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 18, 2023 08:00AM Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dec 12, 2023 08:05AM Blueprint Medicines (BPMC) Granted EU Approval of AYVAKYT
Dec 12, 2023 08:05AM Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
Dec 9, 2023 12:30PM Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
Dec 4, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 28, 2023 08:00AM Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
Nov 10, 2023 08:00AM Blueprint Medicines (BPMC) Receives Positive CHMP Opinion for AYVAKYT
Nov 10, 2023 08:00AM Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
Nov 3, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 26, 2023 07:00AM Blueprint Medicines Reports Third Quarter 2023 Results
Oct 23, 2023 08:30AM Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
Oct 12, 2023 08:00AM Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
Oct 5, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 5, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2023 04:16PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 2, 2023 07:00AM Blueprint Medicines Reports Second Quarter 2023 Results
Jul 19, 2023 08:00AM Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
Jul 5, 2023 04:30PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 5, 2023 05:00PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 3, 2023 09:00AM Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
May 23, 2023 10:00AM Blueprint Medicines (BPMC) Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial
May 23, 2023 10:00AM NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
View Older Stories